



**Peter Goldschmidt**  
**Chairman of the Executive Board/CEO**

**Bio**

Since Sep. 1st 2018, Peter Goldschmidt is CEO of STADA Arzneimittel AG. He strongly pursues the STADA vision, to be the partner of choice in generics and consumer health in Europe and selected emerging markets, while continuously outgrowing the industry in terms of growth and profitability.

Peter Goldschmidt has 28 years' experience and success in the pharmaceutical industry with Novartis Pharma. He worked in OTC, Generics and the innovative Pharma Business in Asia, Europe and the US in several different leadership functions. From 2013 through 2018, Peter Goldschmidt was President of Sandoz US and Head of North America. He served on the Board of Directors as Vice Chair of Association for Accessible Medicines (AAM), the generics and biosimilar industry association in the U.S. Prior to this, Head of Sandoz Central and Eastern Europe and member of the Global Sandoz Executive Committee.

While at Sandoz North America he led the organization through several years of growth in the US through its generic and biosimilar portfolio expansion. By building a strong diverse leadership team he creates a culture where associates are purpose-driven, resilient, engaged and thrive in the face of challenges. Peter Goldschmidt's focus is on driving growth by expanding the portfolio and having strong partnerships in production and commercial activities while ensuring superior customer relations, strong supply chain reliability, ultimately leading to increased market share.

A German national, he is a graduate in politics and economic geography – and hold a master's degree in sociology – from the University of Muenster in Germany. He has completed post-graduate studies at the London Business School, UK, and at the Harvard Business School and Stanford Business School in the US.